StreetAlpha
13F holdings · Q3 2026

Commodore Capital

New York, NY · files as Commodore Capital LP
Know the moment Commodore Capital filesYou follow Commodore Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1831942

Commodore Capital reported 37 stocks worth $1.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RLAY (16.8%), ELVN (11.6%) and ALKS (9.0%). Compared with Q2 2026, the fund opened new positions in DMRA, SRZN and KRSA, added to IFRX and RLMD, trimmed ALKS, SYRE and AMLX and sold out of TNGX, EYPT and CATX.

Latest filing: what Commodore Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
11 new2 added11 trimmed7 sold outBought about $232M · sold about $527M
New 11
See all 11 →
Added 2
Trimmed 11
See all 11 →
Sold out 7
  • TNGX$70.3M
  • EYPT$65.8M
  • Galecto Inc$50.4M
  • CATX$21.6M
  • Nuvalent Inc$12.3M
See all 7 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$1.3B−23.1% vs last quarter
Stocks held3711 new · 7 sold out
Top 5 weight47.7%fairly concentrated
Turnover59%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
RLAY
Relay Therapeutics Inc
$217M16.8%12MNo change6 of 8
2
ELVN
Enliven Therapeutics Inc
$150M11.6%3.3MNo change8 of 8
3
ALKS
Alkermes PLC
$117M9.0%2.9M−125K (−4%)8 of 8
4
ANRO
Alto Neuroscience Inc
$69.5M5.4%2.7MNo change4 of 8
5
SYRE
Spyre Therapeutics Inc
$62.3M4.8%700K−147K (−17%)8 of 8
6
AMLX
Amylyx Pharmaceuticals Inc
$58.2M4.5%2M−3.6M (−65%)5 of 8
7
LBRX
LB Pharmaceuticals Inc
$49.2M3.8%1.3M−218K (−15%)5 of 8
8
DMRA
Damora Therapeutics Inc
$41.3M3.2%1.9MNew position1 of 8
9
COGT
Cogent Biosciences Inc
$40.5M3.1%1.3M−1.8M (−59%)8 of 8
10
TYRA
Tyra Biosciences Inc
$37.7M2.9%1.7M−150K (−8%)7 of 8
🔒 27 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
TNGX
Tango Therapeutics Inc
$70.3M2.3M
EYPT
Eyepoint Pharmaceuticals Inc
$65.8M4.6M
GALECTO INC
$50.4M1.9M
CATX
Perspective Therapeutics Inc
$21.6M6.3M
NUVALENT INC
$12.3M100K

🔒 Free account: see all 7.

Reported value

last 8 quarters
$1.4BQ4 '24
$1.4BQ1 '25
$1.4BQ2 '25
$2BQ3 '25
$1.5BQ4 '25
$1.7BQ1 '26
$1.7BQ2 '26
$1.3BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Commodore Capital 13F FAQ

What does Commodore Capital own?

Commodore Capital reported 37 stocks worth $1.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RLAY (16.8%), ELVN (11.6%) and ALKS (9.0%). The table above lists every position in the filing (the top 10 without an account).

What did Commodore Capital buy and sell in Q3 2026?

Compared with Q2 2026: 11 new positions, 2 added to, 11 trimmed and 7 sold out. New positions include DMRA, SRZN and KRSA. It sold all of TNGX, EYPT and CATX.

When will Commodore Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Commodore Capital's portfolio worth?

The Q3 2026 filing reports $1.3B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.